CHICAGO, IL, Evozyne announced $81 Million in Series B funding led by Fidelity Management & Research Company and OrbiMed.
Evozyne announced $81 Million in Series B funding led by Fidelity Management & Research Company and OrbiMed with participation from NVentures, NVIDIA's venture capital arm. Previous investors Paragon Biosciences and Valor Equity Partners expanded their support in the round.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
